CClinicalTrials.gg
CompletedNCT03059121Updated Jan 28, 2026

The Cleveland Cardiometabolic Cohort

An observational study in HIV and Lipodystrophy, sponsored by University Hospitals Cleveland Medical Center. Completed at 1 site in United States. Open to participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2026-01-28.

Sponsored by University Hospitals Cleveland Medical Center · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
56
Ages
16 Years and older
Sex
All
01

Study summary

In this observational study, the investigators will examine the changes in body composition in HIV-infected subjects before and after initiation of HIV treatment, and look at the correlations with changes in cardiometabolic indices such as endothelial function and coronary calcium scoring.

Read the detailed description

The effects of lifestyle factors on body composition changes after antiretroviral therapy (ART) are unknown, and as such, investigators will use this prospective observational cohort to study relationships between lifestyle factors, including diet, physical activity and illicit drug use, with changes in body composition after ART. In addition, the effect of the body fat changes will be correlated to changes in cardiometabolic indices such as endothelial function and coronary calcium scoring.

02

Conditions studied

  • HIV
  • Lipodystrophy

Browse trials for

Keywords

  • HIV
  • Lipodystrophy
03

Who can participate

Ages eligible
16 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Subjects will be primarily recruited from the practice of the investigator (the Special Immunology Unit (SIU) at University Hospitals Case Medical Center). All subjects seen at the Special Immunology Unit who meet the inclusion/exclusion criteria will be approached for study participation. Subjects who see physicians outside of the SIU may be eligible as well if they contact the study team and meet the inclusion criteria.

Inclusion criteria

  • HIV-1 infection as documented by any licensed ELISA test kit and confirmed by Western blot at any time prior to study entry. HIV-1 culture, HIV-1 antigen, plasma HIV-1 RNA, or a second antibody test by a method other than ELISA is acceptable as an alternative confirmatory test
  • Provides written informed consent and is capable of reading and comprehending the informed consent
  • Is not currently taking antiretroviral therapy and has never been on such treatments in the past. Exception would be for subjects who had been in the past on ≤30 days cumulative antiretrovirals, as long as these were stopped >6 months prior to study entry
  • Is planning on starting antiretroviral therapy as part of routine clinic care

Exclusion criteria

Exclusion Criteria:

  • Pregnancy or lactation
04

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
56 participants (actual)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • HIV-infected ART-naïve

    HIV-infected subjects ≥ 16 years who are ART-naïve starting their first antiretroviral regimen

    Diagnostic Test: Dual-energy X-ray absorptiometry

Interventions

  • Diagnostic testDual-energy X-ray absorptiometry
05

What researchers measure

Primary outcomes

  1. Body composition measures

    Assessed using DEXA (dual energy x-ray absorptiometry) scans which will be quantifying total body fat

    Time frame: Baseline, 6-month, 1 year, 2 year, 3 year, 4 year, 5 year

Secondary outcomes

  1. Resting Energy Expenditure (REE) measures

    Assessed using a BodyGem REE calculator (values in KCal)

    Time frame: Baseline, 6-month, 1 year, 2 year, 3 year, 4 year, 5 year

  2. endothelial function measures

    Assessed using EndoPAT (values reported as a reactive hyperemia index RHI)

    Time frame: Baseline, 6-month, 1 year, 2 year, 3 year, 4 year, 5 year

  3. calcium score measures

    Assessed using CT scans

    Time frame: Baseline, 6-month, 1 year, 2 year, 3 year, 4 year, 5 year

  4. central obesity

    measured with waist circumference using a tape measure (in cm)

    Time frame: Baseline, 6-month, 1 year, 2 year, 3 year, 4 year, 5 year

  5. Lipids measures

    used measuring blood levels of triglycerides (mg/dL); serum high-density lipoprotein (mg/dL) ; cholesterol (mg/dL); low density lipoprotein (mg/dL)

    Time frame: Baseline, 6-month, 1 year, 2 year, 3 year, 4 year, 5 year

  6. Fasting plasma glucose measures

    fasting plasma glucose test is performed after a person has fasted for at least 8 hours (measured in mg/dL)

    Time frame: Baseline, 6-month, 1 year, 2 year, 3 year, 4 year, 5 year

  7. Metabolic syndrome

    Metabolic syndrome will be defined using the following measures: central obesity, serum triglycerides , serum high-density lipoprotein (HDL); cholesterol levels and fasting plasma glucose

    Time frame: Baseline, 6-month, 1 year, 2 year, 3 year, 4 year, 5 year

06

Study locations

1 site
  • University Hospitals Case Medical Center
    Cleveland, Ohio 44106, United States
07

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT03059121
Lead sponsor
University Hospitals Cleveland Medical Center
Responsible party
Grace McComsey (Principle Investigator, University Hospitals Cleveland Medical Center) — Principal investigator
First posted
Feb 23, 2017
Start date
Sep 2016
Primary completion
May 19, 2025
Completion
May 19, 2025
Last update
Jan 28, 2026

Study contacts

Grace McComsey, MD
principal investigator · University Hospitals Cleveland Medical Center

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion